Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
puma biotechnology啓動ALISCA-Breast1 II期臨床試驗,以阿利瑟替治療雌激素受體陽性、HER2陰性轉移性乳腺癌
Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
puma biotechnology啓動ALISCA-Breast1 II期臨床試驗,針對激素受體陽性、HER2陰性的轉移性乳腺癌使用Alisertib。